<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616614</url>
  </required_header>
  <id_info>
    <org_study_id>WAT/CMBP/2015</org_study_id>
    <nct_id>NCT02616614</nct_id>
  </id_info>
  <brief_title>Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75%
      gel. This study is designed to evaluate the safety and efficacy of this formulation in
      subjects with Acne Vulgaris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, three-arm, parallel group, placebo control bioequivalence
      study with clinical endpoint, at multiple study sites, designed to establish bioequivalence
      of clindamycin 1.2% and benzoyl peroxide 3.75% gel of Actavis and Onexton® (clindamycin 1.2%
      and benzoyl peroxide 3.75%) gel in the treatment of subjects with Acne Vulgaris.

      The primary objective is to evaluate the bioequivalence of a generic of clindamycin 1.2% and
      benzoyl peroxide 3.75% gel to Onexton® in the treatment of subjects with acne vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment Success at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where &quot;success&quot; was defined as an IGA score that was at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">862</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Onexton gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin/benzoyl peroxide gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onexton</intervention_name>
    <description>Topical gel for treating acne</description>
    <arm_group_label>Onexton gel</arm_group_label>
    <other_name>Clindamycin/benzoyl peroxide gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin/benzoyl peroxide gel</intervention_name>
    <description>Generic Clindamycin/benzoyl peroxide gel for treating acne</description>
    <arm_group_label>Clindamycin/benzoyl peroxide gel</arm_group_label>
    <other_name>Clindamcyin Phosphate</other_name>
    <other_name>BPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle gel used as a placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
             of acne vulgaris

          -  On the face, ≥25 non-inflammatory lesions (i.e., open and closed comedones) and ≥ 20
             inflammatory lesions (i.e., papules and pustules) and ≤ 2 nodulocystic lesions (i.e.,
             nodules and cysts). For the purposes of study treatment and evaluation, these lesions
             should be limited to the facial treatment area. Counts of nodules and cysts should be
             reported separately and not included in the inflammatory or non-inflammatory lesion
             counts. Lesions involving the eyes and scalp should be excluded from the count.
             (Subjects may have acne lesions on other areas of the body (e.g., on the back)).

          -  Subjects must have Investigator's Global Assessment (IGA) of acne severity grade 2, 3,
             or 4.

          -  Willing to refrain from use of all other topical acne medications or antibiotics
             during the 12 week treatment period. Subjects may use other topical acne treatments
             that do not have significant or measurable systemic absorption for treatment of acne
             of the back, shoulders and chest (e.g. benzoyl peroxide, salicylic acid).

          -  Subjects who are 18 years of age or older must have provided Institutional Review
             Board (IRB) approved written informed consent. Subjects who are at least 12 years of
             age and less than 18 years of age must have provided IRB approved written assent; this
             written assent must be accompanied by an IRB approved written informed consent from
             the subject's legally acceptable representative (i.e., parent or guardian). In
             addition, all subjects or their legally acceptable representatives (i.e., parent or
             guardian) must sign a Health Insurance Portability and Accountability Act (HIPAA)
             authorization, if applicable.

          -  Male subjects and Female subjects of childbearing potential must use accepted methods
             of birth control or must agree to practice abstinence, from study start to 30 days
             after the last administration of study drug. All female subjects are considered to be
             of childbearing potential unless they have been surgically sterilized or have been
             postmenopausal for at least 1 year. Any of the following methods of birth control are
             acceptable: oral contraceptives, contraceptive patches/implants (e.g., Norplant®),
             vaginal ring (NuvaRing®), Depo-Provera® (Medroxy progesterone acetate), double barrier
             methods (e.g., condom and spermicide) or intrauterine device (IUD).

          -  Female subjects of child bearing potential must have a negative urine pregnancy test
             at baseline.

          -  Subjects who use make-up must have used the same brands/types of make-up for a minimum
             period of 14 days prior to study entry and must agree to not change make-up brand/type
             or frequency of use throughout the study.

        Exclusion Criteria:

          -  History of hypersensitivity or allergy to clindamycin or benzoyl peroxide and/or any
             of the study medication ingredients or lincomycin or any other allowed product used
             during the study.

          -  Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
             folliculitis, or bacterial folliculitis).

          -  Excessive facial hair (beards, sideburns, moustaches, etc.) that would interfere with
             diagnosis or assessment of acne vulgaris. Patient is allowed to shave the excessive
             facial hair at least a day before visiting the site for study assessments.

          -  Use within 6 months prior to baseline of oral retinoids (e.g. Accutane®) or
             therapeutic vitamin A supplements of greater than 10,000 units/day.

          -  Use for less than 3 months prior to baseline of estrogens or oral contraceptives; use
             of such therapy must remain constant throughout the study.

          -  Use on the face within 1 month prior to baseline or during the study of: 1)
             cryodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5)
             intralesional steroids, or 6) x-ray therapy.

          -  Use within 1 month prior to baseline of: 1) spironolactone, 2) systemic steroids, 3)
             systemic antibiotics, 4) systemic treatment for acne vulgaris or 5) systemic
             anti-inflammatory agents.

          -  Use within 2 weeks prior to baseline of: 1) topical steroids, 2) topical retinoids, 3)
             topical acne treatments including over-the-counter preparations, 4) topical anti-
             inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.

          -  Subjects who have acne fulminans, and secondary acne (e.g., chloracne and drug induced
             acne) will be excluded from participation.

          -  Female subjects who are pregnant, nursing or planning to become pregnant during study
             participation (Visit 1 through Visit 4 and 30 days post visit 4) will be excluded from
             study participation.

          -  Subjects who have received radiation therapy and/or anti-neoplastic agents within 90
             days prior to baseline will be excluded from study participation.

          -  Subjects who have unstable medical disorders that are clinically significant or
             life-threatening diseases will be excluded from study participation.

          -  Subjects who have on-going malignancies requiring systemic treatment will be excluded
             from study participation. In addition, subjects who have any malignancy of the skin of
             the facial area will be excluded from study participation.

          -  Subjects who engage in activities that involve excessive or prolonged exposure to
             sunlight or weather extremes, such as wind or cold, will be excluded from study
             participation.

          -  Subjects who have facial sunburn will be excluded from study participation

          -  Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or
             use drugs of abuse (including, but not limited to, cannabinoids and cocaine) as judged
             by their medical history will be excluded from study participation.

          -  History or presence of significant smoking (more than 10 cigarettes or any other form
             of tobacco smoking/day or consumption of tobacco products).

          -  Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg, Diastolic blood
             pressure less than 60 mm Hg or more than 90 mm Hg and Pulse rate less than 50
             beats/minute or more than 100 beats/minute.

          -  Subjects who have participated in an investigational drug study (i.e., subjects have
             been treated with an investigational drug) within 1 month prior to baseline will be
             excluded from study participation. Subjects who are participating in non- treatment
             studies such as observational studies or registry studies can be considered for
             inclusion.

          -  Major illness, as per investigator's discretion, during 3 months before screening.

          -  Subjects who have been previously enrolled in this study will be excluded from study
             participation.

          -  Subjects who have had laser therapy and electrodesiccation to the facial area within
             180 days prior to study entry will be excluded from participation.

          -  Subjects who have had cosmetic procedures (e.g., facials) which may affect the
             efficacy and safety profile of the investigational product within 14 days prior to
             study entry will be excluded from participation.

          -  Subjects who have had general anesthesia for any reason and subjects who have received
             neuromuscular blocking agents within 14 days prior to study entry will be excluded
             from study participation.

          -  Subjects who have a baseline score of 3 (severe, marked/intense) as per the
             Application Site Reaction Scale (Section 5.2) will be excluded from participation.

          -  Any employees or staff of the research site are excluded from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry lau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actavis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance Dermatology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estudy</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estudy</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMB Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Assoc</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Assoc</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Research</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DiscoverResearch Inc</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reseacr Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Assoc. of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <results_first_submitted>December 11, 2019</results_first_submitted>
  <results_first_submitted_qc>May 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The populations for this study included the Safety Population, the Per-Protocol Population (PP), and the modified Intent-to-Treat (mITT) Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="P2">
          <title>Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel)</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="325"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PP Population</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="285"/>
                <participants group_id="P3" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>More than 3 applications missed</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="B2">
          <title>Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="329"/>
            <count group_id="B2" value="328"/>
            <count group_id="B3" value="161"/>
            <count group_id="B4" value="818"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread="7.56"/>
                    <measurement group_id="B2" value="20.4" spread="7.04"/>
                    <measurement group_id="B3" value="20.1" spread="6.92"/>
                    <measurement group_id="B4" value="20.4" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="526"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="608"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="559"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</title>
        <description>Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.</description>
        <time_frame>12 weeks</time_frame>
        <population>Using the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Clindamycin and Benzoyl Peroxide</title>
            <description>Clindamycin 1.2% and Benzoyl Peroxide 3.75% gel (Actavis Laboratories SLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference Onexton (Clindamycin and Benzoyl Peroxide)</title>
            <description>Onexton gel (Clindamycin 1.3% and Benzoyl Peroxide 3.75%) (Valeant Pharmaceuticals North America LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Gel</title>
            <description>Vehicle Gel: Placebo product</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</title>
          <description>Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.</description>
          <population>Using the per-protocol population.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.81" spread="36.791"/>
                    <measurement group_id="O2" value="-67.56" spread="28.405"/>
                    <measurement group_id="O3" value="-53.78" spread="40.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% CI for the difference was contained within the interval [0.80,1.25] for the PP population.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts</title>
        <description>One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.</description>
        <time_frame>12 weeks</time_frame>
        <population>Using the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Clindamycin and Benzoyl Peroxide</title>
            <description>Clindamycin 1.2% and Benzoyl Peroxide 3.75% gel (Actavis Laboratories SLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference Onexton (Clindamycin and Benzoyl Peroxide)</title>
            <description>Onexton gel (Clindamycin 1.3% and Benzoyl Peroxide 3.75%) (Valeant Pharmaceuticals North America LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Gel</title>
            <description>Vehicle Gel: Placebo product</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts</title>
          <description>One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.</description>
          <population>Using the per-protocol population.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.58" spread="40.747"/>
                    <measurement group_id="O2" value="-49.50" spread="32.872"/>
                    <measurement group_id="O3" value="-37.50" spread="40.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% CI for the difference was contained within the interval [0.80, 1.25] for the PP population.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment Success at Week 12</title>
        <description>The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where &quot;success&quot; was defined as an IGA score that was at least 2 grades less than the baseline assessment.</description>
        <time_frame>12 weeks</time_frame>
        <population>Using the PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Clindamycin and Benzoyl Peroxide</title>
            <description>Clindamycin 1.2% and Benzoyl Peroxide 3.75% gel (Actavis Laboratories SLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference Onexton (Clindamycin and Benzoyl Peroxide)</title>
            <description>Onexton gel (Clindamycin 1.3% and Benzoyl Peroxide 3.75%) (Valeant Pharmaceuticals North America LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Gel</title>
            <description>Vehicle of the test product (Actavis Laboratories SLC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Success at Week 12</title>
          <description>The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where &quot;success&quot; was defined as an IGA score that was at least 2 grades less than the baseline assessment.</description>
          <population>Using the PP population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bioequivalence was established if the 90% CI for the difference was contained within the interval (-0.20, +0.20).</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% CI for the difference was contained within the interval (-0.20, +0.20).</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.022</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.087</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
            <estimate_desc>Equivalence was based on difference in the number of subjects with success. Bioequivalence was established if the 90% CI for the difference was contained within the interval (-0.20, +0.20).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 12 Weeks</time_frame>
      <desc>Adverse events were collected from participants who were randomized and received the study drug.
Safety population assessment</desc>
      <group_list>
        <group group_id="E1">
          <title>Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="E2">
          <title>Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Gel</title>
          <description>Subjects applied one pea-sized amount of the investigational product to the entire face 1 time each day for a period of 84 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <description>Bee sting with acute allergic reaction, likely anaphlactoid</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cranio-cerebral injury</sub_title>
                <description>Closed head injury</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <description>Spontaneous abortion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Conjunctivitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sinusitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Investigation abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Artificial crown procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

